225 related articles for article (PubMed ID: 25809326)
21. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
[TBL] [Abstract][Full Text] [Related]
22. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.
Pfluger T; Melzer HI; Schneider V; La Fougere C; Coppenrath E; Berking C; Bartenstein P; Weiss M
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):822-31. PubMed ID: 21210112
[TBL] [Abstract][Full Text] [Related]
23. Impact of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer.
Sasaki K; Kawasaki H; Sato M; Koyama K; Yoshimi F; Nagai H
Dig Surg; 2017; 34(1):60-67. PubMed ID: 27454870
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of
Tsuyoshi H; Tsujikawa T; Yamada S; Okazawa H; Yoshida Y
Cancer Imaging; 2020 Oct; 20(1):75. PubMed ID: 33092631
[TBL] [Abstract][Full Text] [Related]
25. Is there any additional benefit of contrast-enhanced CT as part of routine PET/CT protocols for the differentiation of suspicious incidental gastrointestinal 2-deoxy-(18)F-FDG uptake?
Brendle CB; Aschoff P; Kratt T; Schraml C; Reimold M; Claussen CD; Pfannenberg CA
Korean J Radiol; 2013; 14(6):951-9. PubMed ID: 24265572
[TBL] [Abstract][Full Text] [Related]
26. The performance of contrast-enhanced FDG PET/CT for the differential diagnosis of unexpected ovarian mass lesions in patients with nongynecologic cancer.
Lee JW; Lee JH; Cho A; Yun M; Lee JD; Kim YT; Kang WJ
Clin Nucl Med; 2015 Feb; 40(2):97-102. PubMed ID: 25546187
[TBL] [Abstract][Full Text] [Related]
27. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.
Schramm N; Rominger A; Schmidt C; Morelli JN; Schmid-Tannwald C; Meinel FG; Reiser MF; Rist C
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1014-24. PubMed ID: 23503574
[TBL] [Abstract][Full Text] [Related]
28. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.
Altini C; Niccoli Asabella A; Di Palo A; Fanelli M; Ferrari C; Moschetta M; Rubini G
Medicine (Baltimore); 2015 May; 94(20):e864. PubMed ID: 25997066
[TBL] [Abstract][Full Text] [Related]
30. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
31. [Diagnostic value of water enema (18)F-fluorodexyglucose positron emission tomography and computed tomography in incidental finding of hypermetabolism focus in the colorectum].
Zhang Z; Lyu Q; Chen F; Zhang J; Lu D; Hu P; Ma L
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Mar; 17(3):239-44. PubMed ID: 24671811
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of F-18 FDG PET/CECT vs. CECT for detecting recurrence of periampullary carcinoma and its prognostic significance.
Santhosh S; Mittal BR; Kang M; Kapoor R; Gupta R; Rana S; Bhattacharya A; Bhasin D
Abdom Imaging; 2015 Jun; 40(5):1131-7. PubMed ID: 25655637
[TBL] [Abstract][Full Text] [Related]
33. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
[TBL] [Abstract][Full Text] [Related]
34. Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer.
Zhang J; Zuo CJ; Jia NY; Wang JH; Hu SP; Yu ZF; Zheng Y; Zhang AY; Feng XY
World J Gastroenterol; 2015 Mar; 21(10):2988-96. PubMed ID: 25780297
[TBL] [Abstract][Full Text] [Related]
35. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
36. Additional Value of Integrated
Yoo J; Lee JM; Yoon JH; Joo I; Lee DH
Korean J Radiol; 2021 May; 22(5):714-724. PubMed ID: 33660461
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic accuracy of lymph node metastasis depends on metabolic activity of the primary lesion in thoracic squamous esophageal cancer.
Manabe O; Hattori N; Hirata K; Itoh K; Hosokawa M; Takahashi H; Oyama-Manabe N; Tamaki N
J Nucl Med; 2013 May; 54(5):670-6. PubMed ID: 23516310
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis and staging of cardiac masses: additional value of CMR with
Mikail N; Males L; Hyafil F; Benali K; Deschamps L; Brochet E; Ehmer C; Driss AB; Saker L; Rossi A; Alkhoder S; Raffoul R; Rouzet F; Ou P
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2232-2241. PubMed ID: 35247063
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic cancer: diagnosing lymph node metastasis and predicting survival.
Kim HR; Seo M; Nah YW; Park HW; Park SH
Nucl Med Commun; 2018 Jul; 39(7):691-698. PubMed ID: 29893751
[TBL] [Abstract][Full Text] [Related]
40. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
